[1]
|
Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E.M., Dominguez Escrig, J.L., et al. (2022) European Asso-ciation of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). European Urology, 81, 75-94. https://doi.org/10.1016/j.eururo.2021.08.010
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., Laver-sanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[3]
|
van Rhijn, B.W.G., Hentschel, A.E., Bründl, J., Compérat, E.M., Hernán-dez, V., Čapoun, O., et al. (2021) Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-Muscle-Invasive Bladder Cancer: A Multicenter European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 4, 182-191.
|
[4]
|
DeGeorge, K.C., Holt, H.R. and Hodges, S.C. (2017) Bladder Cancer: Diagnosis and Treatment. Ameri-can Family Physician, 96, 507-514.
|
[5]
|
Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., Padala, S.A. and Barsouk, A. (2020) Epidemiology of Bladder Cancer. Medical Sciences (Basel, Switzerland), 8, Article No. 15. https://doi.org/10.3390/medsci8010015
|
[6]
|
Skolarus, T.A., Ye, Z., Zhang, S. and Hollenbeck, B.K. (2010) Re-gional Differences in Early Stage Bladder Cancer Care and Outcomes. Urology, 76, 391-396. https://doi.org/10.1016/j.urology.2009.12.079
|
[7]
|
Packiam, V.T., Werntz, R.P. and Steinberg, G.D. (2019) Cur-rent Clinical Trials in Non-Muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage. Cur-rent Urology Reports, 20, Article No. 84.
https://doi.org/10.1007/s11934-019-0952-y
|
[8]
|
Huang, D.S., Wang, Z., He, X.J., Diplas, B.H., Yang, R., Killela, P.J., et al. (2015) Recurrent TERT Promoter Mutations Identified in a Large-Scale Study of Multiple Tumour Types Are Associated with Increased TERT Expression and Telomerase Activation. European Journal of Cancer (Oxford, England: 1990), 51, 969-976.
https://doi.org/10.1016/j.ejca.2015.03.010
|
[9]
|
Chapman, E.J., Kelly, G. and Knowles, M.A. (2008) Genes In-volved in Differentiation, Stem Cell Renewal, and Tumorigenesis Are Modulated in Telomerase-Immortalized Human Urothelial Cells. Molecular Cancer Research, 6, 1154-1168. https://doi.org/10.1158/1541-7786.MCR-07-2168
|
[10]
|
Kurtis, B., Zhuge, J., Ojaimi, C., Ye, F., Cai, D., Zhang, D., Fallon, J.T. and Zhong, M. (2016) Recurrent TERT Promoter Mutations in Urothelial Carcinoma and Potential Clinical Applications. Annals of Diagnostic Pathology, 21, 7-11. https://doi.org/10.1016/j.anndiagpath.2015.12.002
|
[11]
|
Rachakonda, P.S., Hosen, I., de Verdier, P.J., Fallah, M., Heidenreich, B., Ryk, C., et al. (2013) TERT Promoter Mutations in Bladder Cancer Affect Patient Survival and Disease Recurrence through Modification by a Common Polymorphism. Proceedings of the National Academy of Sciences of the United States of America, 110, 17426-17431.
https://doi.org/10.1073/pnas.1310522110
|
[12]
|
Borah, S., Xi, L., Zaug, A.J., Powell, N.M., Dancik, G.M., Cohen, S.B., et al. (2015) Cancer. TERT Promoter Mutations and Telomerase Reactivation in Urothelial Cancer. Science (New York, N.Y.), 347, 1006-1010.
https://doi.org/10.1126/science.1260200
|
[13]
|
Cheng, L., Davidson, D.D., Wang, M., Lopez-Beltran, A., Montironi, R., Wang, L., et al. (2016) Telomerase Reverse Transcriptase (TERT) Promoter Mutation Analysis of Benign, Malignant and Reactive Urothelial Lesions Reveals a Subpopulation of Inverted Papilloma with Immortalizing Genetic Change. Histopathology, 69, 107-113.
https://doi.org/10.1111/his.12920
|
[14]
|
Cao, W., Ma, E., Zhou, L., Yuan, T. and Zhang, C. (2017) Exploring the FGFR3-Related Oncogenic Mechanism in Bladder Cancer Using Bioinformatics Strategy. World Journal of Surgical Oncology, 15, Article No. 66.
https://doi.org/10.1186/s12957-017-1125-4
|
[15]
|
van Kessel, K.E., Kompier, L.C., de Bekker-Grob, E.W., Zuiver-loon, T.C., Vergouwe, Y., Zwarthoff, E.C. and Steyerberg, E.W. (2013) FGFR3 Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies. The Journal of Urology, 189, 1676-1681. https://doi.org/10.1016/j.juro.2012.11.005
|
[16]
|
Oliushina, E.M., Zavalishina, L.E., Alekseenok, E.Y., Oskina, N.A. andreeva, Y.Y., Kuznetsova, O.A., et al. (2023) Investigation of the Mutational Status of the FGFR3 Gene in Urothelial Bladder Carcinoma. Arkhiv Patologii, 85, 5-12.
https://doi.org/10.17116/patol2023850215
|
[17]
|
Critelli, R., Fasanelli, F., Oderda, M., Polidoro, S., Assumma, M.B., Viberti, C., et al. (2016) Detection of Multiple Mutations in Urinary Exfoliated Cells from Male Bladder Cancer Patients at Diagnosis and during Follow-Up. Oncotarget, 7, 67435-67448. https://doi.org/10.18632/oncotarget.11883
|
[18]
|
Blanca, A., Requena, M.J., Alvarez, J., Cheng, L., Montironi, R., Raspollini, M.R., Reymundo, C. and Lopez-Beltran, A. (2016) FGFR3 and Cyclin D3 as Urine Biomarkers of Bladder Cancer Recurrence. Biomarkers in Medicine, 10, 243-253. https://doi.org/10.2217/bmm.15.120
|
[19]
|
Gou, K., Liu, J., Feng, X., Li, H., Yuan, Y. and Xing, C. (2018) Expression of Minichromosome Maintenance Proteins (MCM) and Cancer Prognosis: A Meta-Analysis. Journal of Cancer, 9, 1518-1526. https://doi.org/10.7150/jca.22691
|
[20]
|
Yu, S., Wang, G., Shi, Y., Xu, H., Zheng, Y. and Chen, Y. (2020) MCMs in Cancer: Prognostic Potential and Mechanisms. Analytical Cellular Pathology (Amsterdam), 2020, Article ID: 3750294. https://doi.org/10.1155/2020/3750294
|
[21]
|
Kelly, J.D., Dudderidge, T.J., Wollenschlaeger, A., Okoturo, O., Burl-ing, K., Tulloch, F., et al. (2012) Bladder Cancer Diagnosis and Identification of Clinically Significant Disease by Com-bined Urinary Detection of Mcm5 and Nuclear Matrix Protein 22. PLOS ONE, 7, e40305. https://doi.org/10.1371/journal.pone.0040305
|
[22]
|
Dudderidge, T., Stockley, J., Nabi, G., Mom, J., Umez-Eronini, N., Hrouda, D., et al. (2020) A Novel, Non-Invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Pa-tients Presenting with Haematuria—A Prospective Multicentre Performance Evaluation of ADXBLADDER. European Urology Oncology, 3, 42-46.
https://doi.org/10.1016/j.euo.2019.06.006
|
[23]
|
Roupret, M., Gontero, P., McCracken, S.R.C., Dudderidge, T., Stockley, J., Kennedy, A., et al. (2020) Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. The Journal of Urology, 204, 685-690.
https://doi.org/10.1097/JU.0000000000001084
|
[24]
|
Sharma, G., Sharma, A., Krishna, M., Ahluwalia, P. and Gautam, G. (2022) Diagnostic Performance of Minichromosome Maintenance 5 (MCM5) in Bladder Cancer: A System-atic Review and Meta-Analysis. Urologic Oncology, 40, 235-242. https://doi.org/10.1016/j.urolonc.2022.03.001
|
[25]
|
Witjes, J.A., Morote, J., Cornel, E.B., Gakis, G., van Valenberg, F.J.P., Lozano, F., et al. (2018) Performance of the Bladder EpiCheck™ Methylation Test for Patients under Surveillance for Non-Muscle-Invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. European Urol-ogy Oncology, 1, 307-313.
https://doi.org/10.1016/j.euo.2018.06.011
|
[26]
|
Su, S.F., de Castro Abreu, A.L., Chihara, Y., Tsai, Y. an-dreu-Vieyra, C., Daneshmand, S., et al. (2014) A Panel of Three Markers Hyper- and Hypomethylated in Urine Sedi-ments Accurately Predicts Bladder Cancer Recurrence. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20, 1978-1989.
https://doi.org/10.1158/1078-0432.CCR-13-2637
|
[27]
|
Reinert, T., Borre, M., Christiansen, A., Hermann, G.G., Ørntoft, T.F. and Dyrskjøt, L. (2012) Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation. PLOS ONE, 7, e46297. https://doi.org/10.1371/journal.pone.0046297
|
[28]
|
Maldonado, L., Brait, M., Michailidi, C., Munari, E., Driscoll, T., Schultz, L., et al. (2014) An Epigenetic Marker Panel for Recurrence Risk Prediction of Low Grade Papillary Urothe-lial Cell Carcinoma (LGPUCC) and Its Potential Use for Surveillance after Transurethral Resection Using Urine. Onco-target, 5, 5218-5233.
https://doi.org/10.18632/oncotarget.2129
|
[29]
|
Yoon, H.Y., Kim, Y.J., Kim, J.S., Kim, Y.W., Kang, H.W., Kim, W.T., et al. (2016) RSPH9 Methylation Pattern as a Prognostic Indicator in Patients with Non-Muscle Invasive Bladder Cancer. Oncology Reports, 35, 1195-1203.
https://doi.org/10.3892/or.2015.4409
|
[30]
|
Wu, Y., Jiang, G., Zhang, N., Liu, S., Lin, X., Perschon, C., et al. (2020) HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria. European Urology Focus, 6, 284-291. https://doi.org/10.1016/j.euf.2018.09.016
|
[31]
|
Deligezer, U., Erten, N., Akisik, E.E. and Dalay, N. (2006) Circu-lating Fragmented Nucleosomal DNA and Caspase-3 mRNA in Patients with Lymphoma and Myeloma. Experimental and Molecular Pathology, 80, 72-76.
https://doi.org/10.1016/j.yexmp.2005.05.001
|
[32]
|
Kavalieris, L., O’Sullivan, P., Frampton, C., Guilford, P., Dar-ling, D., Jacobson, E., et al. (2017) Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. The Journal of Urology, 197, 1419-1426. https://doi.org/10.1016/j.juro.2016.12.010
|
[33]
|
Valenberg, F., Hiar, A.M., Wallace, E., Bridge, J.A., Mayne, D.J., Beqaj, S., et al. (2019) Prospective Validation of an mRNA-Based Urine Test for Surveillance of Patients with Bladder Cancer. European Urology, 75, 853-860.
https://doi.org/10.1016/j.eururo.2018.11.055
|
[34]
|
Chen, L. and Shan, G. (2021) CircRNA in Cancer: Fundamental Mechanism and Clinical Potential. Cancer Letters, 505, 49-57. https://doi.org/10.1016/j.canlet.2021.02.004
|
[35]
|
Meng, X., Yang, D., Zhang, B., Zhao, Y., Zheng, Z. and Zhang, T. (2023) Regulatory Mechanisms and Clinical Applications of Tumor-Driven Exosomal circRNAs in Cancers. Interna-tional Journal of Medical Sciences, 20, 818-835.
https://doi.org/10.7150/ijms.82419
|
[36]
|
Liu, C.X. and Chen, L.L. (2022) Circular RNAs: Characterization, Cellular Roles, and Applications. Cell, 185, 2016-2034. https://doi.org/10.1016/j.cell.2022.04.021
|
[37]
|
Zhang, J., Liu, H., Hou, L., Wang, G., Zhang, R., Huang, Y., Chen, X. and Zhu, J. (2017) Circular RNA_LARP4 Inhibits Cell Proliferation and Invasion of Gastric Cancer by Sponging miR-424-5p and Regulating LATS1 Expression. Molecular Cancer, 16, Article No. 151. https://doi.org/10.1186/s12943-017-0719-3
|
[38]
|
Thomson, D.W. and Dinger, M.E. (2016) En-dogenous microRNA Sponges: Evidence and Controversy. Nature Reviews Genetics, 17, 272-283. https://doi.org/10.1038/nrg.2016.20
|
[39]
|
Bi, J., Liu, H., Dong, W., Xie, W., He, Q., Cai, Z., Huang, J. and Lin, T. (2019) Circular RNA circ-ZKSCAN1 Inhibits Bladder Cancer Progression through miR-1178-3p/p21 Axis and Acts as a Prognostic Factor of Recurrence. Molecular Cancer, 18, Article No. 133. https://doi.org/10.1186/s12943-019-1060-9
|
[40]
|
Yarmishyn, A.A. and Kurochkin, I.V. (2015) Long Noncoding RNAs: A Potential Novel Class of Cancer Biomarkers. Frontiers in Genetics, 6, Article No. 145. https://doi.org/10.3389/fgene.2015.00145
|
[41]
|
Maass, P.G., Luft, F.C. and Bähring, S. (2014) Long Non-Coding RNA in Health and Disease. Journal of Molecular Medicine (Berlin, Germany), 92, 337-346. https://doi.org/10.1007/s00109-014-1131-8
|
[42]
|
Chao, C., Tang, R., Zhao, J., Di, D., Qian, Y. and Wang, B. (2023) Oncogenic Roles and Related Mechanisms of the Long Non-Coding RNA MINCR in Human Cancers. Frontiers in Cell and Developmental Biology, 11, Article ID: 1087337. https://doi.org/10.3389/fcell.2023.1087337
|
[43]
|
Malik, R., Patel, L., Prensner, J.R., Shi, Y., Iyer, M.K., Subramaniyan, S., et al. (2014) The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer. Molecular Cancer Research, 12, 1081-1087.
https://doi.org/10.1158/1541-7786.MCR-14-0257
|
[44]
|
Liu, Z., Wang, W., Jiang, J., Bao, E., Xu, D., Zeng, Y., Tao, L. and Qiu, J. (2013) Downregulation of GAS5 Promotes Bladder Cancer Cell Proliferation, Partly by Regulating CDK6. PLOS ONE, 8, e73991.
https://doi.org/10.1371/journal.pone.0073991
|
[45]
|
Wang, Y., Chen, W., Yang, C., Wu, W., Wu, S., Qin, X. and Li, X. (2012) Long Non-Coding RNA UCA1a(CUDR) Promotes Proliferation and Tumorigenesis of Bladder Cancer. In-ternational Journal of Oncology, 41, 276-284.
|
[46]
|
Lian, P., Wang, Q., Zhao, Y., Chen, C., Sun, X., Li, H., et al. (2019) An Eight-Long Non-Coding RNA Signature as a Candidate Prognostic Biomarker for Bladder Cancer. Aging, 11, 6930-6940. https://doi.org/10.18632/aging.102225
|
[47]
|
Andrew, A.S., Karagas, M.R., Schroeck, F.R., Marsit, C.J., Schned, A.R., Pettus, J.R., Armstrong, D.A. and Seigne, J.D. (2019) MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis. Cancer Epidemiology, Biomarkers & Prevention, 28, 782-788. https://doi.org/10.1158/1055-9965.EPI-18-0884
|
[48]
|
Ding, W., Chen, Z., Gou, Y., Sun, C., Xu, K., Tan, J., et al. (2014) Are EORTC Risk Tables Suitable for Chinese Patients with Non-Muscle-Invasive Bladder Cancer? Cancer Epi-demiology, 38, 157-161.
https://doi.org/10.1016/j.canep.2014.02.001
|
[49]
|
Abufaraj, M., Shariat, S.F., Haitel, A., Moschini, M., Foerster, B., Chłosta, P., et al. (2017) Prognostic Role of N-Cadherin Expression in Patients with Non-Muscle-Invasive Bladder Cancer. Urologic Oncology, 35, 264-271.
https://doi.org/10.1016/j.urolonc.2017.01.012
|